Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer

被引：0
|
作者：
Yoshitaka Saito
Yoh Takekuma
Yoshito Komatsu
Mitsuru Sugawara
机构：
[1] Hokkaido University Hospital,Department of Pharmacy
[2] Hokkaido University Hospital,Cancer Center
[3] Hokkaido University,Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences
来源：
International Journal of Clinical Oncology | 2023年 / 28卷
关键词：
Regorafenib; Severe hypertension; Metastatic colorectal cancer (mCRC); Vascular endothelial growth factor (VEGF); Progression-free survival; Multikinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1183 / 1190
页数：7
相关论文
共 50 条
  • [1] Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer
    Saito, Yoshitaka
    Takekuma, Yoh
    Komatsu, Yoshito
    Sugawara, Mitsuru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (09) : 1183 - 1190
  • [2] Impact of baseline proteinuria on progression-free survival after regorafenib treatment for metastatic colorectal cancer
    Yoshitaka Saito
    Yoh Takekuma
    Yoshito Komatsu
    Mitsuru Sugawara
    Supportive Care in Cancer, 2025, 33 (5)
  • [3] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
    Cicero, Giuseppe
    De Luca, Rossella
    Dieli, Francesco
    ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
  • [4] Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment
    Saito, Yoshitaka
    Takekuma, Yoh
    Komatsu, Yoshito
    Sugawara, Mitsuru
    SUPPORTIVE CARE IN CANCER, 2022, 30 (12) : 10203 - 10211
  • [5] Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment
    Yoshitaka Saito
    Yoh Takekuma
    Yoshito Komatsu
    Mitsuru Sugawara
    Supportive Care in Cancer, 2022, 30 : 10203 - 10211
  • [6] Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer
    Gill, S.
    Berry, S.
    Biagi, J.
    Butts, C.
    Buyse, M.
    Chen, E.
    Jonker, D.
    Marginean, C.
    Samson, B.
    Stewart, J.
    Thirlwell, M.
    Wong, R.
    Maroun, J. A.
    CURRENT ONCOLOGY, 2011, 18 : S5 - S10
  • [7] Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer
    Bowater, Russell J.
    Lilford, Philippa E.
    Lilford, Richard J.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2011, 27 (03) : 207 - 214
  • [8] Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer
    Alandag, Celal
    Karaman, Elanur
    Yuce, Elif
    ANTI-CANCER DRUGS, 2022, 33 (04) : 389 - 393
  • [9] Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint
    Hurvitz, Sara A.
    CANCER TREATMENT REVIEWS, 2011, 37 (07) : 495 - 504
  • [10] Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer
    Chirila, Costel
    Odom, Dawn
    Devercelli, Giovanna
    Khan, Shahnaz
    Sherif, Bintu N.
    Kaye, James A.
    Molnar, Istvan
    Sherrill, Beth
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2012, 27 (05) : 623 - 634
12345